Scalper1 News
Big pharma Pfizer (PFE) got a downgrade ahead of its Q2 earnings report scheduled for Tuesday, a day that will also feature reports from fellow big pharma Merck (MRK) as well as big biotech Amgen (AMGN). Analysts on average expect Pfizer earnings of 57 cents a share, up a penny from the year-earlier quarter, with sales dropping 3.9% to $12.47 billion due to patent expirations. In his downgrade note Monday, BMO Capital Markets analyst Alex Arfaei Scalper1 News
Scalper1 News